Hyphens Pharma International Limited (SGX:1J5)
Singapore
· Delayed Price · Currency is SGD 0.320
-0.005 (-1.54%)
At close: Mar 6, 2026
SGXC:1J5 Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 177.37 | 195.42 | 170.6 | 162.32 | 125.88 | Upgrade
|
| Revenue Growth (YoY) | -9.24% | 14.55% | 5.10% | 28.94% | 4.06% | Upgrade
|
| Cost of Revenue | 106.74 | 127.18 | 109.57 | 100.04 | 78.47 | Upgrade
|
| Gross Profit | 70.63 | 68.24 | 61.03 | 62.28 | 47.41 | Upgrade
|
| Selling, General & Admin | 56.38 | 54.91 | 50.02 | 47.83 | 39.62 | Upgrade
|
| Operating Expenses | 56.38 | 54.91 | 50.02 | 47.83 | 39.62 | Upgrade
|
| Operating Income | 14.25 | 13.34 | 11.01 | 14.45 | 7.79 | Upgrade
|
| Interest Expense | -0.52 | -0.57 | -0.28 | -0.24 | -0.1 | Upgrade
|
| Interest & Investment Income | 0.06 | 0.15 | 0.34 | 0.04 | 0.07 | Upgrade
|
| Earnings From Equity Investments | - | - | 0.55 | 0.47 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.76 | -0.35 | -1.41 | -0.92 | 0.46 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.96 | 0.44 | 0.19 | 0.49 | 0.43 | Upgrade
|
| EBT Excluding Unusual Items | 8.06 | 13.02 | 10.4 | 14.29 | 8.68 | Upgrade
|
| Merger & Restructuring Charges | - | -0.07 | - | - | -0.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.17 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.01 | 0.01 | -0 | -0 | Upgrade
|
| Pretax Income | 8.06 | 12.96 | 10.57 | 14.29 | 8.26 | Upgrade
|
| Income Tax Expense | 1.95 | 2.1 | 1.99 | 2.88 | 1.41 | Upgrade
|
| Earnings From Continuing Operations | 6.12 | 10.86 | 8.58 | 11.41 | 6.85 | Upgrade
|
| Minority Interest in Earnings | -0.27 | -0.66 | -0.01 | -0.06 | - | Upgrade
|
| Net Income | 5.84 | 10.19 | 8.57 | 11.35 | 6.85 | Upgrade
|
| Net Income to Common | 5.84 | 10.19 | 8.57 | 11.35 | 6.85 | Upgrade
|
| Net Income Growth | -42.67% | 18.98% | -24.52% | 65.81% | 11.08% | Upgrade
|
| Shares Outstanding (Basic) | 309 | 309 | 309 | 309 | 301 | Upgrade
|
| Shares Outstanding (Diluted) | 314 | 315 | 309 | 310 | 302 | Upgrade
|
| Shares Change (YoY) | -0.20% | 1.74% | -0.27% | 2.66% | 0.60% | Upgrade
|
| EPS (Basic) | 0.02 | 0.03 | 0.03 | 0.04 | 0.02 | Upgrade
|
| EPS (Diluted) | 0.02 | 0.03 | 0.03 | 0.04 | 0.02 | Upgrade
|
| EPS Growth | -42.59% | 16.97% | -24.32% | 61.23% | 10.73% | Upgrade
|
| Free Cash Flow | 17.99 | -1.12 | 5.34 | 16.32 | 5.34 | Upgrade
|
| Free Cash Flow Per Share | 0.06 | -0.00 | 0.02 | 0.05 | 0.02 | Upgrade
|
| Dividend Per Share | 0.015 | 0.015 | 0.009 | 0.011 | 0.007 | Upgrade
|
| Dividend Growth | - | 74.42% | -22.52% | 65.67% | 8.06% | Upgrade
|
| Gross Margin | 39.82% | 34.92% | 35.77% | 38.37% | 37.66% | Upgrade
|
| Operating Margin | 8.03% | 6.83% | 6.46% | 8.90% | 6.19% | Upgrade
|
| Profit Margin | 3.29% | 5.22% | 5.02% | 6.99% | 5.44% | Upgrade
|
| Free Cash Flow Margin | 10.14% | -0.57% | 3.13% | 10.05% | 4.24% | Upgrade
|
| EBITDA | 17.06 | 14.88 | 12.63 | 16.05 | 9.09 | Upgrade
|
| EBITDA Margin | 9.62% | 7.61% | 7.40% | 9.89% | 7.22% | Upgrade
|
| D&A For EBITDA | 2.81 | 1.54 | 1.62 | 1.6 | 1.3 | Upgrade
|
| EBIT | 14.25 | 13.34 | 11.01 | 14.45 | 7.79 | Upgrade
|
| EBIT Margin | 8.03% | 6.83% | 6.46% | 8.90% | 6.19% | Upgrade
|
| Effective Tax Rate | 24.13% | 16.24% | 18.79% | 20.17% | 17.08% | Upgrade
|
| Advertising Expenses | 9.23 | 9.26 | 8.87 | 8.24 | 8.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.